Jackie Havner and her granddaughter Gracie. Jackie, diagnosed with MS in 1965, was among the consumers testifying about benefits of Fampridine.

Fampridine-SR would treat difficulty walking
On October 14, an FDA advisory committee recommended Fampridine-SR for approval. The FDA is expected to make a final decision on or before October 22. The expected decision will make Fampridine-SR (with the proposed brand name Amaya) the first medication ever approved specifically to treat an MS symptom.

More about the decision
More about Amaya (fampridine)
More about gait problems in MS

The 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (called ECTRIMS) was held September 9-12, 2009, in Dusseldorf, Germany. Good news centered on the progress of oral MS drugs in clinical trials, while disappointments mostly involved novel therapeutic agents, such as lamotrigine, an epilepsy drug.

READ MORE

Meet a primary care physician, social worker, neuropsychologist, psychologist, speech/language pathologist, occupational therapist, physical therapist, physiatrist, nutritionist, and an MS nurse. Hear about what they do.

SEE OUR NEW VIDEOS

This communication is partially sponsored through the generous support of Novartis Pharmaceuticals Corporation; Teva Pharmaceuticals, Inc.; Genentech and Biogen Idec.